Operator

Welcome to Vimian Group Q1 Report 2026 Presentation. [Operator Instructions]

Now I will hand the conference over to the speakers, CEO, Alireza Tajbakhsh; and CFO, Carl-Johan Zetterberg Boudrie. Please go ahead.

Alireza Tajbakhsh
Group CEO & Interim Head of MedTech

Hello. Good morning, everyone, and welcome to Vimian's First Quarter Earnings Call 2026. I'm Ali Tajbakhsh, Group CEO, and I will present the first quarter results together with our CFO, Carl-Johan Zetterberg Boudrie.

Q1 is always an active period for us at Vimian with strong cadence of industry and client events. This provides an early read on customer sentiment, I get valuable feedback across our group businesses, opportunities to engage with industry peers and so on. It's encouraging to see that the strong traffic growth, high engagement and the positive feedback I get from veterinarians from these events are also reflected in the strong start to the year with positive momentum across the group.

Three out of 4 of our segments, Specialty Pharma, Veterinary Services and Diagnostics all delivered double-digit growth in the quarter, well ahead of global animal health market.

We completed 2 acquisitions in the quarter, a diagnostic company, I-Vet, in Italy and the innovative Danish clinic group, Favna. These 2 acquisitions will add in total around EUR 10 million in annual revenues.